<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25406979</article-id><article-id pub-id-type="publisher-id">5014</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-844</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Impact of preoperative anemia on relapse
and survival in breast cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>YingJun</given-names></name><address><email>zhyj143@163.com</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>YuYang</given-names></name><address><email>cyy6381@163.com</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>DongTai</given-names></name><address><email>chendt@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yu</given-names></name><address><email>jiangyu@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wan</given-names></name><address><email>huangwan@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Ouyang</surname><given-names>HanDong</given-names></name><address><email>ouyhd@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Xing</surname><given-names>Wei</given-names></name><address><email>xingwei@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>MuSheng</given-names></name><address><email>zengmsh@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>XiaoMing</given-names></name><address><email>xiexm@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff18"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Weian</given-names></name><address><email>zengwa@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff15"/></contrib><aff id="Aff15"><label/>Anesthesiology Department, State Key Laboratory in South
China, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, PR China </aff><aff id="Aff16"><label/>Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, PR China </aff><aff id="Aff17"><label/>State Key Laboratory in South China, Sun Yat-Sen University Cancer Center, Guangzhou, PR China </aff><aff id="Aff18"><label/>Department of Breast Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, PR China </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>844</elocation-id><history><date date-type="received"><day>9</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Zhang et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is
an Open Access article distributed under the terms of the Creative Commons
Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless
otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Previous studies have shown that preoperative anemia is correlated with the
prognoses of various solid tumors. This study was performed to determine the
effect of preoperative anemia on relapse and survival in patients with breast
cancer.</p></sec><sec><title>Methods</title><p>A total of 2960 patients with breast cancer who underwent surgery between 2002
and 2008 at the Sun Yat-sen University Cancer Center (Guangzhou, PR China) were
evaluated in a retrospective analysis. A total of 2123 qualified patients were
divided into an anemic group [hemoglobin (Hb)&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL, N&#x02009;=&#x02009;535)] and a
nonanemic group (Hb&#x02009;&#x02265;&#x02009;12.0&#x000a0;g/dL, N&#x02009;=&#x02009;1588). The effects of anemia on local
relapse-free survival (LRFS), lymph node metastasis-free survival (LNMFS), distant
metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival
(OS) were assessed using Kaplan&#x02013;Meier analysis. Independent prognostic factors
were identified in the final multivariate Cox proportional hazards regression
model.</p></sec><sec><title>Results</title><p>Among the 2123 women who qualified for the analysis, 535 (25.2%) had a Hb
level&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL. The Kaplan&#x02013;Meier curves showed that anemic patients had
worse LRFS, LNMFS, DMFS, RFS, and OS than nonanemic patients, even in the same
clinical stage of breast cancer. Cox proportional hazards regression model
indicated that preoperative anemia was an independent prognostic factor of LRFS,
LNMFS, DMFS, RFS, and OS for patients with breast cancer.</p></sec><sec><title>Conclusions</title><p>Preoperative anemia was independently associated with poor prognosis of
patients with breast cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Preoperative anemia</kwd><kwd>Breast cancer</kwd><kwd>Relapse</kwd><kwd>Survival</kwd><kwd>Hypoxia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Anemia is a common complication in patients with cancer. It has been reported
that between 30&#x02013;90% of patients with cancer have anemia [<xref ref-type="bibr" rid="CR1">1</xref>]. Most studies have found that pre-treatment
anemia is associated with a worse prognosis in cancer patients [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].
In a meta-analysis, anemic patients with lung cancer, cervicouterine carcinoma, head
and neck cancer, prostate cancer, lymphoma, and multiple myeloma had shorter
survival times than those without anemia. The overall estimated increase in risk was
65% (54&#x02013;77%) [<xref ref-type="bibr" rid="CR6">6</xref>]. Preoperative anemia,
even mild anemia, was independently associated with an increased risk of 30-day
morbidity and mortality in patients undergoing major noncardiac surgery
[<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Breast cancer is one of the most common carcinomas worldwide among women. Tumor
size, nodal status, histological grade, lymphovascular invasion (LVI), gene profile
and Human Epidermal Growth Factor Receptor-2 (HER-2)-positivity are strong
prognostic factors of breast cancer [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Although 41&#x02013;82%
of breast cancer patients develop anemia before surgery, [<xref ref-type="bibr" rid="CR1">1</xref>] few studies have explored the effects of
preoperative anemia on the prognosis of breast cancer. Whether preoperative anemia
has a significant adverse impact on relapse or survival in breast cancer patients is
still controversial [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>In this study, we aimed to determine the effects of preoperative anemia on
relapse (local relapse, lymph node metastasis, distant metastasis, and overall
relapse) and survival (local relapse-free survival, lymph node metastasis-free
survival, distant metastasis-free survival, relapse-free survival, and overall
survival) in patients undergoing breast cancer surgery.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>A total of 2960 patients with breast cancer who underwent surgery between 2002
and 2008 at the Sun Yat-sen University Cancer Center (Guangzhou, PR China) were
evaluated in a retrospective analysis. This study was approved by the ethics
committee of the Sun Yat-sen University Cancer Center. No consent from patients was
needed.</p><p>We defined the preoperative blood hemoglobin (Hb) concentration as the last Hb
measurement before the index operation. We also collected other clinical data for
subsequent analysis, including age, tumor type, tumor (T) and nodal (N) status,
histological grade, estrogen receptor (ER) and progesterone receptor (PR) status,
Human Epidermal Growth Factor Receptor-2 (Her-2) status, body mass index (BMI),
menopausal status, type of surgery, and the use of chemotherapy, radiotherapy,
endocrinotherapy, or targeted therapy. Patients with inadequate information,
T<sub>0</sub> stage cancer, metastases or inoperable tumors, as well
as those treated with neoadjuvant chemotherapy or lost to follow-up were excluded
from this analysis. Finally, 2123 patients were enrolled (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). We defined preoperative anemia as Hb&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL
and mild anemia as 9.0&#x02009;&#x02264;&#x02009;Hb&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL according to the World Health
Organization (WHO) limits for Hb. The patients were divided into two groups based on
this definition: the anemic patients group (Hb&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL) and the nonanemic
patient group (Hb&#x02009;&#x02265;&#x02009;12.0&#x000a0;g/dL).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Flow chart of the patient grouping.</bold>
</p></caption><graphic xlink:href="12885_2014_5014_Fig1_HTML" id="d30e470"/></fig></p><p>We defined local relapse-free survival (LRFS) as the duration from the surgery
date to the date when local relapse was diagnosed. Lymph node metastasis-free
survival (LNMFS) was defined as the duration from the surgery date to the date when
lymph node metastasis was diagnosed. Distant metastasis-free survival (DMFS) was
defined as the duration from the surgery date to the date when distant metastasis
was diagnosed. Relapse-free survival (RFS) was defined as the duration from the
surgery date to the date when any relapse was diagnosed and overall survival (OS) as
the duration from the surgery date to the date of death or the last
follow-up.</p><p>The clinical stages of breast cancer were performed according to the American
Joint Committee on Cancer (AJCC) staging system [<xref ref-type="bibr" rid="CR13">13</xref>]. Stage I included T<sub>1</sub>,
N<sub>0</sub>, M<sub>0</sub>, stage II included IIA
(T<sub>0&#x02013;1</sub>, N<sub>1</sub>, M<sub>0</sub>
or T<sub>2</sub>, N<sub>0</sub>, M<sub>0</sub>)
and IIB (T<sub>2</sub>, N<sub>1</sub>,
M<sub>0</sub> or T<sub>3</sub>, N<sub>0</sub>,
M<sub>0</sub>) and stage III included IIIA
(T<sub>0&#x02013;2</sub>, N<sub>2</sub>, M<sub>0</sub>
or T<sub>3</sub>, N<sub>1&#x02013;2</sub>,
M<sub>0</sub>), IIIB (T<sub>4</sub>,
N<sub>0&#x02013;2</sub>, M<sub>0</sub>) and IIIC (any T,
N<sub>3</sub>, M<sub>0</sub>). Stage IV was not considered
because the patients with metastases were excluded.</p><sec id="Sec3"><title>Statistical analysis</title><p>Patients&#x02019; characteristics (frequency distributions) were analyzed using the
&#x003c7;<sup>2</sup> test (chi-squared test). Spearman rank correlation
coefficients of risk factors for both anemia and nonanemia groups were determined.
We also used the &#x003c7;<sup>2</sup> test to compare the local relapse,
lymph node metastasis, distant metastasis, overall relapse, and mortality rates
between the two groups. The comparison of LRFS, LNMFS, DMFS, RFS, and OS between
anemic and nonanemic groups was performed using Kaplan&#x02013;Meier analysis with the
log-rank test. Multivariate Cox proportional hazards regression model with forward
stepwise approach was constructed to identify independent prognostic factors. Age,
tumor type, T-status, N-status, histologic grade, ER, PR, HER-2, BMI grade,
menopause, type of surgery, anemia, sequential treatment after surgery
(chemotherapy, radiotherapy, hormonal therapy, and targeted therapy) were
predictive variables in the model. All statistical analyses were performed with
SPSS (Statistical Package for the Social Sciences, IBM, NY, USA) version 16.0
software. A <italic>P</italic> value &#x0003c;0.05 was considered
statistically significant.</p></sec></sec><sec id="Sec4" sec-type="results"><title>Results</title><p>Among a total of 2123 female patients qualified for the analysis, 535 (25.2%)
had a Hb level&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL. The median age of the patients was 47.0 (range,
22&#x02013;91) years. There were 484 patients in stage I, 1198 in stage II, and 441 in stage
III, and the corresponding number of anemic patients at each stage was 89 (18.4%),
283 (23.6%), and 163 (37.0%), respectively. Overall, 15.8% of the patients received
locoregional radiotherapy, and 82.1% received adjuvant chemotherapy. Patient
characteristics are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Clinical characteristics of patient by anemia
status</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>
<bold><italic>N</italic></bold>&#x02009;=&#x02009;2123 (%)</th><th>Hb&#x02009;&#x0003c;&#x02009;12&#x000a0;g/dL</th><th>Hb&#x02009;&#x02265;&#x02009;12&#x000a0;g/dL</th><th>
<bold><italic>&#x003c7;</italic></bold>
<sup><bold><italic>2</italic></bold></sup>
</th><th>
<bold><italic>P</italic></bold>
</th></tr><tr><th/><th/><th>
<bold><italic>n</italic></bold>&#x02009;=&#x02009;535 (25.2%)</th><th>
<bold><italic>n</italic></bold>&#x02009;=&#x02009;1588 (74.8%)</th><th/><th/></tr></thead><tbody><tr><td>Age</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;&#x02002;&#x02264;50</td><td align="right">1384 (65.2)</td><td align="right">359 (67.1)</td><td align="right">1025 (64.5)</td><td align="center">1.152</td><td align="center">0.283</td></tr><tr><td>&#x02003;&#x02002;&#x0003e;50</td><td align="right">739 (34.8)</td><td align="right">176 (32.9)</td><td align="right">563 (35.5)</td><td align="center"/><td align="center"/></tr><tr><td>Tumor type</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Invasive ductal carcinoma</td><td align="right">1944 (91.6)</td><td align="right">503 (94.0)</td><td align="right">1441 (90.7)</td><td align="center">5.561</td><td align="center">0.018</td></tr><tr><td>&#x02003;&#x02002;Other</td><td align="right">179 (8.4)</td><td align="right">32 (6.0)</td><td align="right">147 (9.3)</td><td align="center"/><td align="center"/></tr><tr><td>Tumor stage</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;T1</td><td align="right">703 (33.1)</td><td align="right">146 (27.3)</td><td align="right">557 (35.1)</td><td align="center">32.458</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;T2</td><td align="right">1146 (54.0)</td><td align="right">284 (53.1)</td><td align="right">862 (54.3)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;T3 and T4</td><td align="right">274 (12.9)</td><td align="right">105 (19.6)</td><td align="right">169 (10.6)</td><td align="center"/><td align="center"/></tr><tr><td>N stage</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;N0</td><td align="right">1185 (55.8)</td><td align="right">250 (46.7)</td><td align="right">935 (58.8)</td><td align="center">38.534</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;N1</td><td align="right">603 (28.4)</td><td align="right">159 (29.7)</td><td align="right">444 (28.0)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;N2</td><td align="right">211 (9.9)</td><td align="right">78 (14.6)</td><td align="right">133 (8.4)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;N3</td><td align="right">124 (5.8)</td><td align="right">48 (9.0)</td><td align="right">76 (4.8)</td><td align="center"/><td align="center"/></tr><tr><td>Histologic grading</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;G1G2 or Gx</td><td align="right">1680 (79.1)</td><td align="right">425 (79.4)</td><td align="right">1255 (79.0)</td><td align="center">0.041</td><td align="center">0.840</td></tr><tr><td>&#x02003;&#x02002;G3</td><td align="right">443 (20.9)</td><td align="right">110 (20.6)</td><td align="right">333 (21.0)</td><td align="center"/><td align="center"/></tr><tr><td>ER</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Negative</td><td align="right">846 (39.8)</td><td align="right">226 (42.3)</td><td align="right">620 (39.1)</td><td align="center">6.385</td><td align="center">0.041</td></tr><tr><td>&#x02003;&#x02002;Positive</td><td align="right">683 (32.2)</td><td align="right">182 (34.0)</td><td align="right">501 (31.5)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Strongly positive</td><td align="right">594 (28.0)</td><td align="right">127 (23.7)</td><td align="right">467 (29.4)</td><td align="center"/><td align="center"/></tr><tr><td>PR</td><td align="right"/><td align="right"/><td align="right"/><td align="right"/><td align="right"/></tr><tr><td>&#x02003;&#x02002;Negative</td><td align="right">654 (30.8)</td><td align="right">168 (31.4)</td><td align="right">486 (30.6)</td><td align="center">8.078</td><td align="center">0.018</td></tr><tr><td>&#x02003;&#x02002;Positive</td><td align="right">906 (42.7)</td><td align="right">249 (46.5)</td><td align="right">657 (41.4)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Strongly positive</td><td align="right">563 (26.5)</td><td align="right">118 (22.1)</td><td align="right">445 (28.0)</td><td align="center"/><td align="center"/></tr><tr><td>HER-2</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Negative</td><td align="right">1067 (50.3)</td><td align="right">249 (46.5)</td><td align="right">818 (51.5)</td><td align="center">10.315</td><td align="center">0.006</td></tr><tr><td>&#x02003;&#x02002;Positive</td><td align="right">633 (29.8)</td><td align="right">154 (28.8)</td><td align="right">479 (30.2)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Strongly positive</td><td align="right">423 (19.9)</td><td align="right">132 (24.7)</td><td align="right">291 (18.3)</td><td align="center"/><td align="center"/></tr><tr><td>BMI</td><td align="right"/><td align="right"/><td align="right"/><td align="right"/><td align="right"/></tr><tr><td>&#x02003;&#x02002;Low (&#x0003c;18.5)</td><td align="right">151 (7.1)</td><td align="right">47 (8.8)</td><td align="right">104 (6.6)</td><td align="center">25.980</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Normal (18.5&#x02013;22.9)</td><td align="right">929 (43.8)</td><td align="right">276 (51.6)</td><td align="right">653 (41.1)</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;High (&#x0003e;22.9)</td><td align="right">1043 (49.1)</td><td align="right">212 (39.6)</td><td align="right">831 (52.3)</td><td align="center"/><td align="center"/></tr><tr><td>Menopause</td><td align="right"/><td align="right"/><td align="right"/><td align="right"/><td align="right"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1318 (62.1)</td><td align="right">352 (65.8)</td><td align="right">966 (60.8)</td><td align="center">4.188</td><td align="center">0.041</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">805 (37.9)</td><td align="right">183 (34.2)</td><td align="right">622 (39.2)</td><td align="center"/><td align="center"/></tr><tr><td>Type of surgery</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;Modified radical mastectomy</td><td align="right">2092 (98.5)</td><td align="right">531 (99.3)</td><td align="right">1561 (98.3)</td><td align="center">2.524</td><td align="center">0.112</td></tr><tr><td>&#x02003;&#x02002;Breast-conserving surgery</td><td align="right">31 (1.5)</td><td align="right">4 (0.7)</td><td align="right">27 (1.7)</td><td align="center"/><td align="center"/></tr><tr><td>Chemotherapy</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">381 (17.9)</td><td align="right">89 (16.6)</td><td align="right">292 (18.4)</td><td align="center">0.835</td><td align="center">0.361</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">1742 (82.1)</td><td align="right">446 (83.4)</td><td align="right">1296 (81.6)</td><td align="center"/><td align="center"/></tr><tr><td>Radiotherapy</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1842 (86.8)</td><td align="right">452 (84.5)</td><td align="right">1390 (87.5)</td><td align="center">3.232</td><td align="center">0.072</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">281 (13.2)</td><td align="right">83 (15.5)</td><td align="right">198 (12.5)</td><td align="center"/><td align="center"/></tr><tr><td>Hormonal therapy</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1366 (64.3)</td><td align="right">347 (64.9)</td><td align="right">1019 (64.2)</td><td align="center">0.083</td><td align="center">0.773</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">757 (35.7)</td><td align="right">188 (35.1)</td><td align="right">569 (35.8)</td><td align="center"/><td align="center"/></tr><tr><td>Targeted therapy</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">2109 (99.3)</td><td align="right">530 (99.1)</td><td align="right">1579 (99.4)</td><td align="center">-</td><td align="center">0.361<sup>a</sup>
</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">14 (0.7)</td><td align="right">5 (0.9)</td><td align="right">9 (0.6)</td><td align="center"/><td align="center"/></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Fisher's exact test.</p><p>
<italic>Abbreviations: Hb</italic> hemoglobin, <italic>PR</italic> partial response, <italic>BMI</italic> body mass index.</p></table-wrap-foot></table-wrap></p><p>The relation between Hb levels and various risk factors was examined by Spearman
rank correlation coefficients. As shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, we found that there was a significant positive correlation
between Hb levels and BMI, and a negative correlation with T- and N-status and
clinical stages.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Spearman&#x02019;s rank correlation of the hemoglobin levels
and various clinical characteristics</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Hb</th><th>
<bold><italic>P</italic></bold>
</th></tr></thead><tbody><tr><td align="center">Age</td><td align="center">0.035</td><td align="center">0.101</td></tr><tr><td align="center">Tumor type</td><td align="center">0.014</td><td align="center">0.509</td></tr><tr><td align="center">T stage</td><td align="center">&#x02212;0.078</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">N stage</td><td align="center">&#x02212;0.051</td><td align="center">0.019</td></tr><tr><td align="center">Clinical stage</td><td align="center">&#x02212;0.085</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Histologic grading</td><td align="center">0.010</td><td align="center">0.653</td></tr><tr><td align="center">ER</td><td align="center">0.029</td><td align="center">0.181</td></tr><tr><td align="center">PR</td><td align="center">0.016</td><td align="center">0.460</td></tr><tr><td align="center">HER-2</td><td align="center">&#x02212;0.035</td><td align="center">0.103</td></tr><tr><td align="center">BMI</td><td align="center">0.134</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Chemotherapy</td><td align="center">&#x02212;0.025</td><td align="center">0.242</td></tr><tr><td align="center">Radiotherapy</td><td align="center">&#x02212;0.014</td><td align="center">0.521</td></tr><tr><td align="center">Hormonal therapy</td><td align="center">0.002</td><td align="center">0.912</td></tr><tr><td align="center">Targeted therapy</td><td align="center">&#x02212;0.034</td><td align="center">0.115</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations: Hb</italic> hemoglobin, <italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor, <italic>HER-2</italic> Human Epidermal Growth Factor Receptor-2, <italic>BMI</italic> body mass index.</p></table-wrap-foot></table-wrap></p><p>After a median follow-up time of 67&#x000a0;months, 61 patients (2.9%) underwent local
relapse, 105 (4.9%) had lymph node metastases, and 269 (12.7%) had distant
metastases among 2123 breast cancer patients. Local relapse was diagnosed in 7.3% of
anemic patients versus 1.4% of nonanemic patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). For lymph node metastasis, distant metastasis, and any
relapse, the percentages were 12.1% versus 2.5% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), 26.7% versus 7.9% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and 38.7% versus 9.9% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), respectively. Mortality was 24.5% in anemic group
versus 7.7% in nonanemic group (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001)
(Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The relapse rate and mortality
were significantly different between the anemic and nonanemic groups.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Prevalence of relapses and deaths in patients with and
without anemia</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>
<bold><italic>N</italic></bold>&#x02009;=&#x02009;2123</th><th>Hb&#x02009;&#x0003c;&#x02009;12&#x000a0;g/dL</th><th>Hb&#x02009;&#x02265;&#x02009;12&#x000a0;g/dL</th><th>
<bold><italic>&#x003c7;</italic></bold>
<sup>2</sup>
</th><th>
<bold><italic>P</italic></bold>
</th></tr><tr><th/><th/><th>
<bold><italic>n</italic></bold>&#x02009;=&#x02009;535 (%)</th><th>
<bold><italic>n</italic></bold>&#x02009;=&#x02009;1588 (%)</th><th/><th/></tr></thead><tbody><tr><td>Local relapse</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">2062</td><td align="right">496 (92.7)</td><td align="right">1566 (98.6)</td><td align="center">49.989</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">61</td><td align="right">39 (7.3)</td><td align="right">22 (1.4)</td><td align="center"/><td align="center"/></tr><tr><td>Lymph node metastasis</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">2018</td><td align="right">470 (87.9)</td><td align="right">1548 (97.5)</td><td align="center">78.950</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">105</td><td align="right">65 (12.1)</td><td align="right">40 (2.5)</td><td align="center"/><td align="center"/></tr><tr><td>Distant metastasis</td><td align="right"/><td align="right"/><td align="right"/><td align="right"/><td align="right"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1854</td><td align="right">392 (73.3)</td><td align="right">1462 (92.1)</td><td align="center">127.7</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">269</td><td align="right">143 (26.7)</td><td align="right">126 (7.9)</td><td align="center"/><td align="center"/></tr><tr><td>Any relapse</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1758</td><td align="right">328 (61.3)</td><td align="right">1430 (90.1)</td><td align="center">232.2</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">365</td><td align="right">207 (38.7)</td><td align="right">158 (9.9)</td><td align="center"/><td align="center"/></tr><tr><td>Death</td><td align="right"/><td align="right"/><td align="right"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02002;No</td><td align="right">1869</td><td align="right">404 (75.5)</td><td align="right">1465 (92.3)</td><td align="center">106.5</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02002;Yes</td><td align="right">254</td><td align="right">131 (24.5)</td><td align="right">123 (7.7)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviation:</italic>
<italic>Hb</italic> hemoglobin.</p></table-wrap-foot></table-wrap></p><p>In the univariate analysis, LRFS, LNMFS, DMFS, RFS, and OS were significantly
shorter in anemic patients than those in nonanemic patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 for all) (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Additionally, stratified analysis by different clinical stages
(stages I to III) of breast cancer showed that LRFS, LNMFS, DMFS, RFS and OS were
all significantly shorter in anemic patients (Figures&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). Among the 2123 anemic patients, 2104 had mild
anemia (9.0&#x02009;&#x02264;&#x02009;Hb&#x02009;&#x0003c;&#x02009;12.0&#x000a0;g/dL). Survivals were also significantly shorter even in
patients with mild anemia (Figure&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>LRFS, LNMFS, DMFS, RFS, and OS of patients with and
without anemia. A</bold>. LRFS for patients with Hb&#x02009;&#x02265;&#x02009;12&#x000a0;g/dL versus
Hb&#x02009;&#x0003c;&#x02009;12&#x000a0;g/dL. <bold>B</bold>. LNMFS for patients with
Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL. <bold>C</bold>. DMFS
for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL. <bold>D</bold>. RFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL.
<bold>E</bold>. OS for patients with Hb &#x02265;12&#x000a0;g/dL
versus Hb &#x0003c;12&#x000a0;g/dL.</p></caption><graphic xlink:href="12885_2014_5014_Fig2_HTML" id="d30e1968"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>LRFS, LNMFS, DMFS, RFS, and OS of patients in stage I
with and without anemia. A</bold>. LRFS for patients with Hb &#x02265;12&#x000a0;g/dL
versus Hb &#x0003c;12&#x000a0;g/dL in stage I. <bold>B</bold>. LNMFS
for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage I. <bold>C</bold>. DMFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb
&#x0003c;12&#x000a0;g/dL in stage I. <bold>D</bold>. RFS for patients
with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage I. <bold>E</bold>. OS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in
stage I.</p></caption><graphic xlink:href="12885_2014_5014_Fig3_HTML" id="d30e1992"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>LRFS, LNMFS, DMFS, RFS, and OS for patients in stage
II with and without anemia. A</bold>. LRFS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage II. <bold>B</bold>. LNMFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL
in stage II. <bold>C</bold>. DMFS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage II. <bold>D</bold>. RFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in
stage II. <bold>E</bold>. OS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage II.</p></caption><graphic xlink:href="12885_2014_5014_Fig4_HTML" id="d30e2016"/></fig><fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>LRFS, LNMFS, DMFS, RFS, and OS for patients in stage
III with and without anemia. A</bold>. LRFS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage III. <bold>B</bold>. LNMFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL
in stage III. <bold>C</bold>. DMFS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage III. <bold>D</bold>. RFS for patients with Hb &#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in
stage III. <bold>E</bold>. OS for patients with Hb
&#x02265;12&#x000a0;g/dL versus Hb &#x0003c;12&#x000a0;g/dL in stage III.</p></caption><graphic xlink:href="12885_2014_5014_Fig5_HTML" id="d30e2040"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>LRFS, LNMFS, DMFS, RFS, and OS for patients without
anemia versus mild anemia. A</bold>. LRFS for patients with Hb
&#x02265;12&#x000a0;g/dL versus 9&#x02009;&#x0003c;&#x02009;Hb &#x0003c;12&#x000a0;g/dL. <bold>B</bold>.
LNMFS for patients with Hb &#x02265;12&#x000a0;g/dL versus 9&#x02009;&#x0003c;&#x02009;Hb &#x0003c;12&#x000a0;g/dL. <bold>C</bold>. DMFS for patients with Hb &#x02265;12&#x000a0;g/dL versus
9&#x02009;&#x0003c;&#x02009;Hb &#x0003c;12&#x000a0;g/dL. <bold>D</bold>. RFS for patients
with Hb &#x02265;12&#x000a0;g/dL versus 9&#x02009;&#x0003c;&#x02009;Hb &#x0003c;12&#x000a0;g/dL. <bold>E</bold>. OS for patients with Hb &#x02265;12&#x000a0;g/dL versus 9&#x02009;&#x0003c;&#x02009;Hb
&#x0003c;12&#x000a0;g/dL.</p></caption><graphic xlink:href="12885_2014_5014_Fig6_HTML" id="d30e2064"/></fig></p><p>Multivariate analysis with all relevant prognostic factors in a Cox proportional
hazards regression model showed that preoperative anemia was a significant
prognostic factor in breast cancer patients (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). T-status (&#x02265;T<sub>3</sub>), N-status
(N<sub>1</sub>, N<sub>2</sub>), strongly positive PR
status and HER-2 positivity were significantly associated with LRFS, and anemic
patients had a 4.939-fold increased relative risk of developing local relapse
compared with nonanemic patients. Only the N-status (N<sub>1</sub>,
N<sub>2</sub>) was significantly associated with LNMFS, with a
5.160-fold increased relative risk of developing lymph node metastasis for anemic
patients compared with nonanemic patients. With respect to DMFS and OS, T-status
(&#x02265;T<sub>3</sub>) and N-status
(N<sub>1</sub>-N<sub>3</sub>) still had significant
associations, and the relative risks of developing distant metastasis and death in
the anemic group were 3.192-fold and 2.849-fold higher than those in the nonanemic
group, respectively. For RFS, T-status (&#x02265;T<sub>3</sub>), N-status
(N<sub>1</sub>&#x02013;N<sub>3</sub>), and strongly positive PR
status were shown to be significant prognostic factors. Anemic patients had a
4.104-fold increased relative risk of developing any relapse compared with nonanemic
patients.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Multivariate analysis of prognostic factors for LRFS,
LNMFS, DMFS, RFS, and OS</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>LRFS</th><th>LNMFS</th><th>DMFS</th><th>RFS</th><th>OS</th><th/><th/><th/><th/><th/></tr><tr><th/><th>HR (95% CI)</th><th>
<bold><italic>P</italic></bold>
</th><th>HR (95% CI)</th><th>
<bold><italic>P</italic></bold>
</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th></tr></thead><tbody><tr><td>T stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;T<sub>1</sub>
</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">NS</td><td align="center">NS</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;T<sub>2</sub>
</td><td align="center">1.045 (0.532&#x02013;2.050)</td><td align="center">0.899</td><td align="center">NS</td><td align="center">NS</td><td align="center">1.333 (0.962&#x02013;1.847)</td><td align="center">0.084</td><td align="center">1.287 (0.976&#x02013;1.697)</td><td align="center">0.074</td><td align="center">1.291 (0.925&#x02013;1.803)</td><td align="center">0.134</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;&#x02265;T<sub>3</sub>
</td><td align="center">2.676 (1.267&#x02013;5.653)</td><td align="center">0.010</td><td align="center">NS</td><td align="center">NS</td><td align="center">1.983 (1.347&#x02013;2.920)</td><td align="center">0.001</td><td align="center">2.021 (1.455&#x02013;2.807)</td><td align="center">&#x0003c;0.001</td><td align="center">2.020 (1.371&#x02013;2.975)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>N stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;N<sub>0</sub>
</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;N<sub>1</sub>
</td><td align="center">2.601 (1.366&#x02013;4.963)</td><td align="center">0.004</td><td align="center">2.235 (1.366&#x02013;3.657)</td><td align="center">0.001</td><td align="center">2.040 (1.493&#x02013;2.788)</td><td align="center">&#x0003c;0.001</td><td align="center">2.009 (1.544&#x02013;2.615)</td><td align="center">&#x0003c;0.001</td><td align="center">1.942 (1.404&#x02013;2.687)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;N<sub>2</sub>
</td><td align="center">2.708 (1.122&#x02013;6.534)</td><td align="center">0.027</td><td align="center">3.742 (2.058&#x02013;6.805)</td><td align="center">&#x0003c;0.001</td><td align="center">3.484 (2.358&#x02013;5.147)</td><td align="center">&#x0003c;0.001</td><td align="center">3.016 (2.152&#x02013;4.225)</td><td align="center">&#x0003c;0.001</td><td align="center">4.200 (2.854&#x02013;6.181)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;N<sub>3</sub>
</td><td align="center">2.450 (0.859&#x02013;6.989)</td><td align="center">0.094</td><td align="center">2.045 (0.912&#x02013;4.487)</td><td align="center">0.083</td><td align="center">4.822 (3.175&#x02013;7.323)</td><td align="center">&#x0003c;0.001</td><td align="center">3.856 (2.672&#x02013;5.565)</td><td align="center">&#x0003c;0.001</td><td align="center">5.083 (3.307&#x02013;7.812)</td><td align="center">&#x0003c;0.001</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;ER</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Negative</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">NS</td><td align="center">NS</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">
<italic>Ref</italic>
</td><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Positive</td><td align="center">0.525 (0.261&#x02013;1.057)</td><td align="center">0.071</td><td align="center">NS</td><td align="center">NS</td><td align="center">0.670 (0.479&#x02013;0.937)</td><td align="center">0.019</td><td align="center">0.726 (0.547&#x02013;0.965)</td><td align="center">0.027</td><td align="center">0.845 (0.598&#x02013;1.194)</td><td align="center">0.340</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Strongly positive</td><td align="center">0.340 (0.144&#x02013;0.803)</td><td align="center">0.014</td><td align="center">NS</td><td align="center">NS</td><td align="center">0.804 (0.537&#x02013;1.206)</td><td align="center">0.292</td><td align="center">0.757 (0.534&#x02013;1.074)</td><td align="center">0.119</td><td align="center">0.566 (0.360&#x02013;0.890)</td><td align="center">0.014</td></tr><tr><td>PR</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Negative</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">
<italic>Ref</italic>
</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Positive</td><td align="center">1.709 (0.826&#x02013;3.535)</td><td align="center">0.149</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">1.409 (1.066&#x02013;1.861)</td><td align="center">0.016</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Strongly positive</td><td align="center">2.989 (1.236&#x02013;7.228)</td><td align="center">0.015</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">0.899 (0.611&#x02013;1.322)</td><td align="center">0.588</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>HER-2</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Negative</td><td align="center">
<italic>Ref</italic>
</td><td align="center"/><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Positive</td><td align="center">2.179 (1.232&#x02013;3.855)</td><td align="center">0.007</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>&#x02003;&#x02003;&#x02003;&#x02009;Strongly positive</td><td align="center">0.651 (0.292&#x02013;1.451)</td><td align="center">0.294</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td><td align="center">NS</td></tr><tr><td>Hormonal therapy</td><td align="center">NS</td><td align="center">NS</td><td align="center">0.537 (0.335&#x02013;0.859)</td><td align="center">0.009</td><td align="center">NS</td><td align="center">NS</td><td align="center">0.733 (0.575&#x02013;0.933)</td><td align="center">0.012</td><td align="center">0.682 (0.503&#x02013;0.926)</td><td align="center">0.014</td></tr><tr><td>Anemia</td><td align="center">4.939 (2.875&#x02013;8.484)</td><td align="center">&#x0003c;0.001</td><td align="center">5.160 (3.428&#x02013;7.767)</td><td align="center">&#x0003c;0.001</td><td align="center">3.192 (2.489&#x02013;4.094)</td><td align="center">&#x0003c;0.001</td><td align="center">4.104 (3.310&#x02013;5.089)</td><td align="center">&#x0003c;0.001</td><td align="center">2.849 (2.205&#x02013;3.680)</td><td align="center">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations:</italic>
<italic>LRFS</italic> local relapse-free survival, <italic>LNMFS</italic> lymph node metastasis-free survival,
<italic>DMFS</italic> distant metastasis-free survival,
<italic>RFS</italic> relapse-free survival, <italic>OS</italic> overall survival, <italic>ER</italic> estrogen receptor, <italic>PR</italic>
progesterone receptor, <italic>HER-2</italic> Human
Epidermal Growth Factor Receptor-2, <italic>HR</italic>
hazard ration, <italic>CI</italic> confidence interval,
<italic>Ref</italic>: Reference group; NS: No
significance.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5" sec-type="discussion"><title>Discussion</title><p>Preoperative anemia has been reported to be associated with poor prognosis in
many types of tumors [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In our present study, a low preoperative Hb
level was shown to be associated with local and distant relapses in breast cancer
patients. Shorter survival was also observed in anemic patients. To the best of our
knowledge, our study was the first to discover that preoperative Hb levels were
associated with tumor (T) and nodal (N) status of breast cancer and BMI. Further,
the most important study finding was that preoperative anemia was shown to be an
independently prognostic factor for LRFS, LNMFS, DMFS, RFS, and OS in breast cancer
patients, even in the same clinical stage or at lower stages.</p><p>Causes of anemia in cancer patients are multifactorial and can be considered as
results of cancer invasion, induced by treatment (after radiotherapy or
chemotherapy), or chronic kidney disease [<xref ref-type="bibr" rid="CR15">15</xref>]. Among the three factors mentioned above, the first one is the
largest contributor. Cancer itself can cause or exacerbate anemia in several ways
[<xref ref-type="bibr" rid="CR16">16</xref>]. Cancer cells may suppress
hematopoiesis via bone marrow infiltration directly. They also generate cytokines
that lead to functional iron deficiency, which decreases the production and shorten
the survival of red blood cells [<xref ref-type="bibr" rid="CR17">17</xref>].
Also, chronic blood loss at tumor sites through cancer cells infiltration can
exacerbate anemia. Other indirect effects include nutritional deficiencies of iron,
folate, and vitamin B12 secondary to anorexia or hemolysis by immune-mediated
antibodies. For the factors mentioned above, it is plausible that preoperative
anemia is more frequent in higher clinical stages and low BMI in association with
malnutrition.</p><p>Many studies supported that pre-treatment Hb levels during adjuvant or
neoadjuvant chemotherapy were related to the prognosis of breast cancer. However,
few studies focused on the preoperative Hb levels [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Kandemir et al. reported that preoperative
anemia was an independent risk factor of disease-free survival and overall survival
in 336 early-stage breast cancer patients [<xref ref-type="bibr" rid="CR11">11</xref>]. Our results not only supported their conclusion but also
showed that preoperative anemia was associated with local relapse-free survival,
lymph node metastasis-free survival, and distant metastasis-free survival in a
larger cohort.</p><p>There are several possible mechanisms by which anemia may reduce survival, and
hypoxia is the most important one. Anemia can reduce the capacity of the blood to
transport oxygen (O<sub>2</sub>), further contributing to the
development of hypoxia. Hypoxia is a common characteristic of locally advanced solid
tumors that has been associated with greater recurrence, less locoregional control,
diminished therapeutic responses, and lower overall and disease-free survival
[<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The association between the blood Hb concentration (cHb) and
the tumor oxygenation status has been examined [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. The median
pO<sub>2</sub> values in breast cancer tumors are lower than those in
the normal breast, which exponentially increase with increasing cHb values
[<xref ref-type="bibr" rid="CR28">28</xref>]. In normal breast tissue, the
O<sub>2</sub> tensions are approximately at a mean
pO<sub>2</sub> of 65&#x000a0;mmHg. However, in breast cancer tissue, the
median pO<sub>2</sub> is 28&#x000a0;mmHg. Further, nearly 60% of breast cancers
contain hypoxic tissue areas with pO<sub>2</sub> values &#x0003c;2.5&#x000a0;mmHg
[<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Hypoxia can lead to structural and functional abnormalities in the tumor
microvasculature, an adverse diffusion geometry and tumor-related anemia result in a
reduced O<sub>2</sub> transport capacity of the blood [<xref ref-type="bibr" rid="CR30">30</xref>]. A key regulator of this process is
hypoxia-inducible factor-1 (HIF-1). HIF-1 is a molecular determinant that responds
to hypoxia. Its expression increases as the pathologic stages progress, and it is
higher in poorly differentiated lesions than in well-differentiated lesions
[<xref ref-type="bibr" rid="CR31">31</xref>]. HIF-1 activity mediates
angiogenesis [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>], epithelial-mesenchymal transition
[<xref ref-type="bibr" rid="CR25">25</xref>], genetic mutations, resistance
to apoptosis, and resistance to radiotherapy and chemotherapy [<xref ref-type="bibr" rid="CR34">34</xref>] in regions of intratumoral hypoxia. More
recent studies have suggested that HIF-1&#x003b1; is a significant positive regulator of
tumor progression, metastasis, and poor patient prognosis [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], and higher
expression of HIF-1&#x003b1; has been shown to correlate with poorer survival in breast
cancer patients [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. This effect was independent of standard
prognostic factors, such as tumor stage and nodal status [<xref ref-type="bibr" rid="CR37">37</xref>]. Some results of our study may be attributed
to hypoxia and HIF-1&#x003b1; activity. It was interesting that preoperative Hb levels were
negatively related to tumor (T) and nodal (N) status of breast cancer, which were
both traditional prognostic factors of breast cancer. However, anemia also impaired
various survival outcomes independently even in the same clinical stage.</p><p>Although preoperative anemia was not related to the sequential postoperative
treatment in our study, most of the data supported the notion that pretreatment
anemia may influence the effects of sequential postoperative treatment. The reason
may be that preoperative anemia contributes to hypoxia in cancer cells. There is
increasing evidence that hypoxic cancer cells are likely to be resistant to
radiotherapy, chemotherapy, and targeted therapy. Thus, the potential for invasion,
metastasis and patient mortality is increased further [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Hypoxia leads
to therapeutic resistance directly through a lack of O<sub>2</sub>,
which radiation and some chemotherapeutic drugs require to exert their cytotoxicity.
Hypoxia also leads to resistance indirectly through changes in cellular metabolism,
proliferation kinetics, the cell-cycle position, the hypoxia-driven proteome, and
genome and clonal selection [<xref ref-type="bibr" rid="CR21">21</xref>,
<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Although hypoxia may be a reasonable explanation for the association between
anemia and survival of breast cancer, there was no direct evidence of hypoxia in
cancer cells in our large population study. Emerging new tools that can measure the
local Hb level and O<sub>2</sub> tension directly in tumor tissues may
solve this problem in the future. Our study provided a clue for further
investigations to clarify the complex mechanisms of hypoxia in breast cancer.</p><p>Since preoperative anemia was associated with poor prognosis in breast cancer
patients in our study, would patients benefit from anemia treatment preoperatively?
Or could we improve the prognosis after administering treatment for anemia? The
answer to this question is somewhat ambiguous because of the complexity of anemia.
For most of patients with breast cancer without chemotherapy, preoperative anemia
was caused by multiple etiologies, including blood loss, functional iron deficiency,
erythropoietin deficiency secondary to renal disease, tumoral marrow involvement,
well as other factors. Evaluation of anemia should be performed carefully before
treatment because an unsuitable treatment might lead to adverse effects. The most
common treatment options for anemic patients include iron therapy, red cell
transfusion, and erythropoietic-stimulating agents. For iron therapy, nutritional
status (iron, total iron binding capacity, ferritin, transferrin saturation, folate,
and vitamin B<sub>12</sub>) and renal function should be evaluated. Only
absolute iron deficiency will benefit from intravenous or oral iron monotherapy
[<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Unfortunately the absence of data regarding the nutritional
status and renal function of our patients impeded further analysis.</p><p>Red cell transfusion is an acceptable treatment option for anemic breast cancer
patients, especially for those requiring rapid improvement of Hb levels. However,
large-scale studies involving cancer patients found that red cell transfusion was
associated with increased thrombosis risk as well as increased mortality risk
[<xref ref-type="bibr" rid="CR40">40</xref>]. Additionally, mild anemia
accounted for 99% anemic patients in this study; thus, transfusions might not be
necessary. As for erythropoietic-stimulating agent therapy, it was suitable only for
patients receiving palliative, myelosuppressive chemotherapy with a Hb &#x0003c;10&#x000a0;g/dL
and without absolute iron deficiency [<xref ref-type="bibr" rid="CR39">39</xref>]. Notably, there were few reports focusing on the relationship
between preoperative Hb and prognosis. However, most treatments for anemia were
derived from the prognostic outcomes of patients with chemotherapy-induced anemia.
Thus, whether preoperative anemia and chemotherapy-induced anemia are both
associated with poor prognosis of patients with breast cancer remains to be
clarified. The question of what is the best approach for patients with preoperative
anemia remains unanswered. Therefore, further studies will be needed to answer these
questions.</p></sec><sec id="Sec6" sec-type="conclusions"><title>Conclusions</title><p>Preoperative anemia is a negative prognostic factor for survival of patients
with breast cancer. However, it still merits further experimental and clinical
investigations.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>LRFS</term><def><p>Local relapse free survival</p></def></def-item><def-item><term>LNMFS</term><def><p>Lymph node metastasis free survival</p></def></def-item><def-item><term>DMFS</term><def><p>Distance metastasis free survival</p></def></def-item><def-item><term>RFS</term><def><p>Relapse free survival</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>LVI</term><def><p>Lymphovascular invasion</p></def></def-item><def-item><term>HER-2</term><def><p>Human epidermal growth factor receptor-2</p></def></def-item><def-item><term>Hb</term><def><p>Hemoglobin</p></def></def-item><def-item><term>TNM</term><def><p>Tumor-Node-Metastasis</p></def></def-item><def-item><term>ER</term><def><p>Estrogen receptor</p></def></def-item><def-item><term>PR</term><def><p>Progesterone receptor</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term>cHb</term><def><p>Blood hemoglobin concentration</p></def></def-item><def-item><term>HIF-1</term><def><p>Hypoxia-inducible factor-1.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>YJ Zhang carried out the design and drafted the manuscript. YY Chen
performed the interpretation of the data and statistical analysis. DT Chen, Y Jiang,
W Huang, HD Ouyang and W Xing participated in acquisition of data. MS Zeng and XM
Xie participated in the critical revision of the manuscript for important
intellectual content. WA Zeng carried out the major design and funding support, and
performed supervision and coordination with other departments. All authors read and
approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by the Natural Science Foundation of China (NSFC)
(No. 81271246) and Doctoral program foundation of State Education Ministry No.
(20120171110096).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>K</given-names></name><name><surname>Wade</surname><given-names>S</given-names></name><name><surname>Balducci</surname><given-names>L</given-names></name></person-group><article-title>Prevalence and outcomes of anemia in cancer: a
systematic review of the literature</article-title><source>Am J Med</source><year>2004</year><volume>116</volume><issue>Suppl 7A</issue><fpage>11S</fpage><lpage>26S</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2003.12.008</pub-id><?supplied-pmid 15050883?><pub-id pub-id-type="pmid">15050883</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>LB</given-names></name></person-group><article-title>Impact of anemia in patients with head and neck cancer
treated with radiation therapy</article-title><source>Curr Treat Options Oncol</source><year>2005</year><volume>6</volume><issue>1</issue><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s11864-005-0011-4</pub-id><?supplied-pmid 15610713?><pub-id pub-id-type="pmid">15610713</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Yi</surname><given-names>CM</given-names></name><name><surname>Sin</surname><given-names>JI</given-names></name><name><surname>Ye</surname><given-names>GW</given-names></name><name><surname>Shin</surname><given-names>IH</given-names></name><name><surname>Lee</surname><given-names>TS</given-names></name></person-group><article-title>Impact of hemoglobin on survival of cervical carcinoma
patients treated with concurrent chemoradiotherapy is dependent on lymph node
metastasis findings by magnetic resonance imaging</article-title><source>Int J Gynecol Cancer</source><year>2006</year><volume>16</volume><issue>5</issue><fpage>1846</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1438.2006.00666.x</pub-id><?supplied-pmid 17009981?><pub-id pub-id-type="pmid">17009981</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grogan</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>GM</given-names></name><name><surname>Melamed</surname><given-names>I</given-names></name><name><surname>Wong</surname><given-names>FL</given-names></name><name><surname>Pearcey</surname><given-names>RG</given-names></name><name><surname>Joseph</surname><given-names>PK</given-names></name><name><surname>Portelance</surname><given-names>L</given-names></name><name><surname>Crook</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name></person-group><article-title>The importance of hemoglobin levels during
radiotherapy for carcinoma of the cervix</article-title><source>Cancer</source><year>1999</year><volume>86</volume><issue>8</issue><fpage>1528</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19991015)86:8&#x0003c;1528::AID-CNCR20&#x0003e;3.0.CO;2-E</pub-id><?supplied-pmid 10526282?><pub-id pub-id-type="pmid">10526282</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunphy</surname><given-names>EP</given-names></name><name><surname>Petersen</surname><given-names>IA</given-names></name><name><surname>Cox</surname><given-names>RS</given-names></name><name><surname>Bagshaw</surname><given-names>MA</given-names></name></person-group><article-title>The influence of initial hemoglobin and blood pressure
levels on results of radiation therapy for carcinoma of the
prostate</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1989</year><volume>16</volume><issue>5</issue><fpage>1173</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/0360-3016(89)90277-0</pub-id><?supplied-pmid 2715066?><pub-id pub-id-type="pmid">2715066</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caro</surname><given-names>JJ</given-names></name><name><surname>Salas</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Goss</surname><given-names>G</given-names></name></person-group><article-title>Anemia as an independent prognostic factor for
survival in patients with cancer: a systemic, quantitative review</article-title><source>Cancer</source><year>2001</year><volume>91</volume><issue>12</issue><fpage>2214</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20010615)91:12&#x0003c;2214::AID-CNCR1251&#x0003e;3.0.CO;2-P</pub-id><?supplied-pmid 11413508?><pub-id pub-id-type="pmid">11413508</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musallam</surname><given-names>KM</given-names></name><name><surname>Tamim</surname><given-names>HM</given-names></name><name><surname>Richards</surname><given-names>T</given-names></name><name><surname>Spahn</surname><given-names>DR</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Habbal</surname><given-names>A</given-names></name><name><surname>Khreiss</surname><given-names>M</given-names></name><name><surname>Dahdaleh</surname><given-names>FS</given-names></name><name><surname>Khavandi</surname><given-names>K</given-names></name><name><surname>Sfeir</surname><given-names>PM</given-names></name><name><surname>Soweid</surname><given-names>A</given-names></name><name><surname>Hoballah</surname><given-names>JJ</given-names></name><name><surname>Taher</surname><given-names>AT</given-names></name><name><surname>Jamali</surname><given-names>FR</given-names></name></person-group><article-title>Preoperative anaemia and postoperative outcomes in
non-cardiac surgery: a retrospective cohort study</article-title><source>Lancet</source><year>2011</year><volume>378</volume><issue>9800</issue><fpage>1396</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61381-0</pub-id><?supplied-pmid 21982521?><pub-id pub-id-type="pmid">21982521</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Louwman</surname><given-names>MW</given-names></name><name><surname>Ribot</surname><given-names>JG</given-names></name><name><surname>Roukema</surname><given-names>JA</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name></person-group><article-title>An overview of prognostic factors for long-term
survivors of breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2008</year><volume>107</volume><issue>3</issue><fpage>309</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1007/s10549-007-9556-1</pub-id><?supplied-pmid 17377838?><pub-id pub-id-type="pmid">17377838</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cianfrocca</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>LJ</given-names></name></person-group><article-title>Prognostic and predictive factors in early-stage
breast cancer</article-title><source>Oncologist</source><year>2004</year><volume>9</volume><issue>6</issue><fpage>606</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.9-6-606</pub-id><?supplied-pmid 15561805?><pub-id pub-id-type="pmid">15561805</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voduc</surname><given-names>KD</given-names></name><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Tyldesley</surname><given-names>S</given-names></name><name><surname>Gelmon</surname><given-names>K</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Kennecke</surname><given-names>H</given-names></name></person-group><article-title>Breast cancer subtypes and the risk of local and
regional relapse</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>10</issue><fpage>1684</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.24.9284</pub-id><?supplied-pmid 20194857?><pub-id pub-id-type="pmid">20194857</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandemir</surname><given-names>EG</given-names></name><name><surname>Mayadagli</surname><given-names>A</given-names></name><name><surname>Turken</surname><given-names>O</given-names></name><name><surname>Yaylaci</surname><given-names>M</given-names></name><name><surname>Ozturk</surname><given-names>A</given-names></name></person-group><article-title>Pre-treatment haemoglobin concentration is a
prognostic factor in patients with early-stage breast cancer</article-title><source>J Int Med Res</source><year>2005</year><volume>33</volume><issue>3</issue><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1177/147323000503300307</pub-id><?supplied-pmid 15938593?><pub-id pub-id-type="pmid">15938593</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>DU</given-names></name><name><surname>Lebrecht</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Siggelkow</surname><given-names>W</given-names></name><name><surname>Lindner</surname><given-names>C</given-names></name><name><surname>Litz</surname><given-names>A</given-names></name><name><surname>Ulbrich</surname><given-names>E</given-names></name><name><surname>Koelbl</surname><given-names>H</given-names></name></person-group><article-title>Prognostic impact of haemoglobin levels in breast
cancer</article-title><source>Anticancer Res</source><year>2007</year><volume>27</volume><issue>2</issue><fpage>1223</fpage><lpage>1226</lpage><?supplied-pmid 17465267?><pub-id pub-id-type="pmid">17465267</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singletary</surname><given-names>SE</given-names></name><name><surname>Allred</surname><given-names>C</given-names></name><name><surname>Ashley</surname><given-names>P</given-names></name><name><surname>Bassett</surname><given-names>LW</given-names></name><name><surname>Berry</surname><given-names>D</given-names></name><name><surname>Bland</surname><given-names>KI</given-names></name><name><surname>Borgen</surname><given-names>PI</given-names></name><name><surname>Clark</surname><given-names>G</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Hughes</surname><given-names>LL</given-names></name><name><surname>Hutter</surname><given-names>RV</given-names></name><name><surname>Morrow</surname><given-names>M</given-names></name><name><surname>Page</surname><given-names>DL</given-names></name><name><surname>Recht</surname><given-names>A</given-names></name><name><surname>Theriault</surname><given-names>RL</given-names></name><name><surname>Thor</surname><given-names>A</given-names></name><name><surname>Weaver</surname><given-names>DL</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>Greene</surname><given-names>FL</given-names></name></person-group><article-title>Revision of the American Joint Committee on Cancer
staging system for breast cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><issue>17</issue><fpage>3628</fpage><lpage>3636</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.02.026</pub-id><?supplied-pmid 12202663?><pub-id pub-id-type="pmid">12202663</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordella</surname><given-names>C</given-names></name><name><surname>Luebbers</surname><given-names>HT</given-names></name><name><surname>Rivelli</surname><given-names>V</given-names></name><name><surname>Gratz</surname><given-names>KW</given-names></name><name><surname>Kruse</surname><given-names>AL</given-names></name></person-group><article-title>An evaluation of the preoperative hemoglobin level as
a prognostic factor for oral squamous cell carcinoma</article-title><source>Head Neck Oncol</source><year>2011</year><volume>3</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1758-3284-3-35</pub-id><?supplied-pmid 21843350?><pub-id pub-id-type="pmid">21843350</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilreath</surname><given-names>JA</given-names></name><name><surname>Stenehjem</surname><given-names>DD</given-names></name><name><surname>Rodgers</surname><given-names>GM</given-names></name></person-group><article-title>Diagnosis and treatment of cancer-related
anemia</article-title><source>Am J Hematol</source><year>2014</year><volume>89</volume><issue>2</issue><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1002/ajh.23628</pub-id><?supplied-pmid 24532336?><pub-id pub-id-type="pmid">24532336</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>GL</given-names></name><name><surname>Raftery</surname><given-names>J</given-names></name><name><surname>Bohlius</surname><given-names>J</given-names></name><name><surname>Brunskill</surname><given-names>S</given-names></name><name><surname>Sandercock</surname><given-names>J</given-names></name><name><surname>Bayliss</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name><name><surname>Stanworth</surname><given-names>S</given-names></name><name><surname>Hyde</surname><given-names>C</given-names></name></person-group><article-title>A systematic review and economic evaluation of epoetin
alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer,
especially that attributable to cancer treatment</article-title><source>Health Technol Assess</source><year>2007</year><volume>11</volume><issue>13</issue><fpage>1</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.3310/hta11130</pub-id><?supplied-pmid 17408534?><pub-id pub-id-type="pmid">17408534</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>CA</given-names></name><name><surname>Steensma</surname><given-names>DP</given-names></name></person-group><article-title>Pure red cell aplasia associated with thymoma:
clinical insights from a 50-year single-institution experience</article-title><source>Br J Haematol</source><year>2006</year><volume>135</volume><issue>3</issue><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06295.x</pub-id><?supplied-pmid 17032177?><pub-id pub-id-type="pmid">17032177</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubsky</surname><given-names>P</given-names></name><name><surname>Sevelda</surname><given-names>P</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name><name><surname>Hausmaninger</surname><given-names>H</given-names></name><name><surname>Samonigg</surname><given-names>H</given-names></name><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Denison</surname><given-names>U</given-names></name><name><surname>Mlineritsch</surname><given-names>B</given-names></name><name><surname>Steger</surname><given-names>G</given-names></name><name><surname>Kwasny</surname><given-names>W</given-names></name><name><surname>St&#x000f6;ger</surname><given-names>H</given-names></name><name><surname>Bartsch</surname><given-names>R</given-names></name><name><surname>Stierer</surname><given-names>M</given-names></name><name><surname>Taucher</surname><given-names>S</given-names></name><name><surname>Fridrik</surname><given-names>M</given-names></name><name><surname>Schippinger</surname><given-names>W</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>P&#x000f6;tter</surname><given-names>R</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><collab>Austrian Breast and Colorectal Cancer Study
Group</collab></person-group><article-title>Anemia is a significant prognostic factor in local
relapse-free survival of premenopausal primary breast cancer patients receiving
adjuvant cyclophosphamide/methotrexate/5-fluorouracil
chemotherapy</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>7</issue><fpage>2082</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-2068</pub-id><?supplied-pmid 18381948?><pub-id pub-id-type="pmid">18381948</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters-Engl</surname><given-names>C</given-names></name><name><surname>Cassik</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Denison</surname><given-names>U</given-names></name><name><surname>Medl</surname><given-names>M</given-names></name><name><surname>Pokieser</surname><given-names>W</given-names></name><name><surname>Sevelda</surname><given-names>P</given-names></name></person-group><article-title>Impact of haemoglobin levels during adjuvant
chemotherapy on the survival of patients with primary breast
cancer</article-title><source>Acta Oncol</source><year>2005</year><volume>44</volume><issue>2</issue><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1080/02841860510007530-1</pub-id><?supplied-pmid 15788291?><pub-id pub-id-type="pmid">15788291</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name></person-group><article-title>The role of hypoxia-induced factors in tumor
progression</article-title><source>Oncologist</source><year>2004</year><volume>9</volume><issue>Suppl 5</issue><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.9-90005-10</pub-id><?supplied-pmid 15591418?><pub-id pub-id-type="pmid">15591418</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>L</given-names></name><name><surname>Blackwell</surname><given-names>K</given-names></name></person-group><article-title>Hypoxia and anemia: factors in decreased sensitivity
to radiation therapy and chemotherapy?</article-title><source>Oncologist</source><year>2004</year><volume>9</volume><issue>Suppl 5</issue><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.9-90005-31</pub-id><?supplied-pmid 15591420?><pub-id pub-id-type="pmid">15591420</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Hockel</surname><given-names>M</given-names></name></person-group><article-title>Impact of hemoglobin levels on tumor oxygenation: the
higher, the better?</article-title><source>Strahlenther Onkol</source><year>2006</year><volume>182</volume><issue>2</issue><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00066-006-1543-7</pub-id><?supplied-pmid 16447012?><pub-id pub-id-type="pmid">16447012</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Briest</surname><given-names>S</given-names></name><name><surname>Hockel</surname><given-names>M</given-names></name></person-group><article-title>Hypoxia in breast cancer: role of blood flow, oxygen
diffusion distances, and anemia in the development of oxygen
depletion</article-title><source>Adv Exp Med Biol</source><year>2005</year><volume>566</volume><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/0-387-26206-7_44</pub-id><?supplied-pmid 16594170?><pub-id pub-id-type="pmid">16594170</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>L</given-names></name></person-group><article-title>Tumor hypoxia: causative factors, compensatory
mechanisms, and cellular response</article-title><source>Oncologist</source><year>2004</year><volume>9</volume><issue>Suppl 5</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.9-90005-4</pub-id><?supplied-pmid 15591417?><pub-id pub-id-type="pmid">15591417</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teicher</surname><given-names>BA</given-names></name></person-group><article-title>Acute and chronic in vivo therapeutic
resistance</article-title><source>Biochem Pharmacol</source><year>2009</year><volume>77</volume><issue>11</issue><fpage>1665</fpage><lpage>1673</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2009.01.006</pub-id><?supplied-pmid 19428320?><pub-id pub-id-type="pmid">19428320</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>LB</given-names></name><name><surname>Chadha</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>RJ</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Shasha</surname><given-names>D</given-names></name></person-group><article-title>Impact of tumor hypoxia and anemia on radiation
therapy outcomes</article-title><source>Oncologist</source><year>2002</year><volume>7</volume><issue>6</issue><fpage>492</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.7-6-492</pub-id><?supplied-pmid 12490737?><pub-id pub-id-type="pmid">12490737</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Thews</surname><given-names>O</given-names></name><name><surname>Hoeckel</surname><given-names>M</given-names></name></person-group><article-title>Treatment resistance of solid tumors: role of hypoxia
and anemia</article-title><source>Med Oncol</source><year>2001</year><volume>18</volume><issue>4</issue><fpage>243</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1385/MO:18:4:243</pub-id><?supplied-pmid 11918451?><pub-id pub-id-type="pmid">11918451</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Briest</surname><given-names>S</given-names></name><name><surname>Hockel</surname><given-names>M</given-names></name></person-group><article-title>Oxygenation gain factor: a novel parameter
characterizing the association between hemoglobin level and the oxygenation
status of breast cancers</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>22</issue><fpage>7634</fpage><lpage>7637</lpage><?supplied-pmid 14633681?><pub-id pub-id-type="pmid">14633681</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Briest</surname><given-names>S</given-names></name><name><surname>Hockel</surname><given-names>M</given-names></name></person-group><article-title>Hypoxia in breast cancer: pathogenesis,
characterization and biological/therapeutic implications</article-title><source>Wien Med Wochenschr</source><year>2002</year><volume>152</volume><issue>13&#x02013;14</issue><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1046/j.1563-258X.2002.02032.x</pub-id><?supplied-pmid 12168517?><pub-id pub-id-type="pmid">12168517</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockel</surname><given-names>M</given-names></name><name><surname>Vaupel</surname><given-names>P</given-names></name></person-group><article-title>Tumor hypoxia: definitions and current clinical,
biologic, and molecular aspects</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><issue>4</issue><fpage>266</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.4.266</pub-id><?supplied-pmid 11181773?><pub-id pub-id-type="pmid">11181773</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Hanrahan</surname><given-names>CF</given-names></name><name><surname>Mommers</surname><given-names>EC</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Pinedo</surname><given-names>HM</given-names></name><name><surname>Abeloff</surname><given-names>MD</given-names></name><name><surname>Simons</surname><given-names>JW</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>van der Wall</surname><given-names>E</given-names></name></person-group><article-title>Levels of hypoxia-inducible factor-1 alpha during
breast carcinogenesis</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><issue>4</issue><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.4.309</pub-id><?supplied-pmid 11181778?><pub-id pub-id-type="pmid">11181778</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>T</given-names></name><name><surname>Schnitzer</surname><given-names>S</given-names></name><name><surname>Brune</surname><given-names>B</given-names></name></person-group><article-title>Tumor hypoxia and cancer progression</article-title><source>Cancer Lett</source><year>2006</year><volume>237</volume><issue>1</issue><fpage>10</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.05.028</pub-id><?supplied-pmid 16002209?><pub-id pub-id-type="pmid">16002209</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name></person-group><article-title>Hypoxia: a key regulator of angiogenesis in
cancer</article-title><source>Cancer Metastasis Rev</source><year>2007</year><volume>26</volume><issue>2</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s10555-007-9066-y</pub-id><?supplied-pmid 17603752?><pub-id pub-id-type="pmid">17603752</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varlotto</surname><given-names>J</given-names></name><name><surname>Stevenson</surname><given-names>MA</given-names></name></person-group><article-title>Anemia, tumor hypoxemia, and the cancer
patient</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><issue>1</issue><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.04.049</pub-id><?supplied-pmid 16111569?><pub-id pub-id-type="pmid">16111569</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name></person-group><article-title>Hypoxia in cancer: significance and impact on clinical
outcome</article-title><source>Cancer Metastasis Rev</source><year>2007</year><volume>26</volume><issue>2</issue><fpage>225</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1007/s10555-007-9055-1</pub-id><?supplied-pmid 17440684?><pub-id pub-id-type="pmid">17440684</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vleugel</surname><given-names>MM</given-names></name><name><surname>Greijer</surname><given-names>AE</given-names></name><name><surname>Shvarts</surname><given-names>A</given-names></name><name><surname>van der Groep</surname><given-names>P</given-names></name><name><surname>van Berkel</surname><given-names>M</given-names></name><name><surname>Aarbodem</surname><given-names>Y</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>van der Wall</surname><given-names>E</given-names></name></person-group><article-title>Differential prognostic impact of hypoxia induced and
diffuse HIF-1alpha expression in invasive breast cancer</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><issue>2</issue><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1136/jcp.2004.019885</pub-id><?supplied-pmid 15677538?><pub-id pub-id-type="pmid">15677538</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname><given-names>P</given-names></name></person-group><article-title>Prognostic potential of the pre-therapeutic tumor
oxygenation status</article-title><source>Adv Exp Med Biol</source><year>2009</year><volume>645</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/978-0-387-85998-9_36</pub-id><?supplied-pmid 19227477?><pub-id pub-id-type="pmid">19227477</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>GM</given-names></name></person-group><article-title>A perspective on the evolution of management of
cancer- and chemotherapy-induced anemia</article-title><source>J Natl Compr Canc Netw</source><year>2012</year><volume>10</volume><issue>4</issue><fpage>434</fpage><lpage>437</lpage><?supplied-pmid 22491043?><pub-id pub-id-type="pmid">22491043</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>GR</given-names></name><name><surname>Becker</surname><given-names>PS</given-names></name><name><surname>Blinder</surname><given-names>M</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Chanan-Khan</surname><given-names>A</given-names></name><name><surname>Cleeland</surname><given-names>C</given-names></name><name><surname>Coccia</surname><given-names>PF</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Gilreath</surname><given-names>JA</given-names></name><name><surname>Kraut</surname><given-names>EH</given-names></name><name><surname>Matulonis</surname><given-names>UA</given-names></name><name><surname>Millenson</surname><given-names>MM</given-names></name><name><surname>Reinke</surname><given-names>D</given-names></name><name><surname>Rosenthal</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>RN</given-names></name><name><surname>Soff</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>RS</given-names></name><name><surname>Vlahovic</surname><given-names>G</given-names></name><name><surname>Weir</surname><given-names>AB</given-names><suffix>3rd</suffix></name></person-group><article-title>Cancer- and chemotherapy-induced anemia</article-title><source>J Natl Compr Canc Netw</source><year>2012</year><volume>10</volume><issue>5</issue><fpage>628</fpage><lpage>653</lpage><?supplied-pmid 22570293?><pub-id pub-id-type="pmid">22570293</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khorana</surname><given-names>AA</given-names></name><name><surname>Francis</surname><given-names>CW</given-names></name><name><surname>Blumberg</surname><given-names>N</given-names></name><name><surname>Culakova</surname><given-names>E</given-names></name><name><surname>Refaai</surname><given-names>MA</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name></person-group><article-title>Blood transfusions, thrombosis, and mortality in
hospitalized patients with cancer</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><issue>21</issue><fpage>2377</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1001/archinte.168.21.2377</pub-id><?supplied-pmid 19029504?><pub-id pub-id-type="pmid">19029504</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR41"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/844/prepub">http://www.biomedcentral.com/1471-2407/14/844/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>
